Biotricity Inc. (BTCY) stock
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Biotricity Inc. grew revenue 13.4% to $16.40M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $1.15M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.15M
- P/E ratio
- –
- Price to sales
- 0.07
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $16.40M
- Net income
- -$2.69M
- EPS, diluted
- -$0.14
- Book value per share
- -$1.53
- Diluted shares
- 23M
Trading
- Previous close
- $0.05
- Open
- $0.05
- Day's range
- $0.05 – $0.05
- Volume
- 41,141
- Average volume (20 days)
- 69,015
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BTCY | S&P 500 | Difference | BTCY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -40.9% | +0.6% | −41.5 pts | ||
| 3 months | -55.7% | +3.4% | −59.0 pts | ||
| Year to date | -83.3% | +13.3% | −96.6 pts | ||
| 1 year | -92.2% | +16.6% | −108.8 pts | ||
| 3 years | -97.7% | +86.4% | −184.1 pts | -71.5% | +23.1% |
| 5 years | -99.7% | +81.9% | −181.6 pts | -69.4% | +12.7% |
| 10 years | -99.7% | +318.9% | −418.6 pts | -44.3% | +15.4% |
Eleven years at a glance
Fiscal years 2013 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biotricity filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Biotricity
Surgical & Medical Instruments & Apparatus
Biotricity Inc. is a medical technology company that provides biometric data monitoring and remote patient monitoring solutions focused on diagnostic and chronic care management. The company primarily targets the ambulatory cardiac outpatient monitoring market, developing products for both clinical and consumer use. Its clinical technologies include the Bioflux mobile cardiac outpatient monitoring system and the Biocore three-lead cardiac monitoring device line, featuring the cellular Biocore Pro patch for electrocardiogram and arrhythmia detection. For consumers, Biotricity offers the Bioheart continuous heart monitor, alongside chronic disease platforms such as Biokit and Biocare. The company sells its diagnostic devices and recurring utilization-based monitoring services to clinics, physicians' offices, hospitals, and independent diagnostic testing facilities.
Company profile, executives and historyBiotricity stock: common questions
What is Biotricity's stock price?
BTCY closed at $0.05 on Oct 19, 2026, up 8.70% on the day.
What is Biotricity's market cap?
Biotricity was worth $1.15M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BTCY's P/E ratio?
Biotricity lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.14), so it has no meaningful P/E ratio.
How much revenue does Biotricity make?
Biotricity reported revenue of $16.40M for the twelve months to Jun 30, 2026, up 13.4% from a year earlier.
Does Biotricity pay a dividend?
No. Biotricity has not paid a cash dividend over the last twelve months.
How has BTCY stock performed over the past year?
Including dividends, BTCY returned -92.2% over the past year, against +16.6% for the S&P 500.
Who are Biotricity's competitors?
Companies most similar to Biotricity by business, industry and size include EBRCZ, DRIO, PLSM, NSPR, VVOS.
See a number that looks wrong?